YD Bio Ltd to Acquire Immunocell Therapy Firm SSMC for $26.87M, Bolstering Biotech Portfolio
YDES has more than doubled off its 52-week low of $5.3.
Summary
YD Bio Ltd has entered a binding Letter of Intent to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd. for approximately $26.87 million, a strategic move to integrate advanced immunocell therapy capabilities and expand its biotechnology ecosystem.
Key Events · M&A and Partnerships · YDES
-
Strategic Acquisition Announced
YD Bio Ltd signed a binding Letter of Intent (LOI) to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd. (SSMC), a Taiwan-based dendritic cell immunotherapy platform.
-
Significant Transaction Value
The total consideration for the acquisition is approximately US$26.87 million (NT$839,832,000).
-
Payment Structure and Lock-ups
Consideration includes a mix of cash and newly issued YD Bio Ltd ordinary shares, with specific shareholders receiving shares subject to 6-month to 1-year lock-up periods.
-
Expansion into Advanced Therapeutics
SSMC specializes in immunocell therapy, including a Phase III clinical application for glioblastoma, significantly expanding YD Bio Ltd's therapeutic pipeline and R&D capabilities.
Analysis · YDES · Industrial Applications And Services
This acquisition represents a significant step in YD Bio Ltd's strategic transformation, as outlined in previous filings. By acquiring SSMC, a company specializing in advanced immunocell therapy with a Phase III clinical asset for glioblastoma, YD Bio Ltd is expanding its R&D capabilities and product portfolio beyond diagnostics into therapeutic solutions. The deal, valued at approximately $26.87 million, will be paid in a mix of cash and shares, with lock-up periods for the new shares. This move is expected to enhance the company's position in the rapidly evolving field of cell and gene therapies and provides a critical new product pipeline.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, YDES was trading at $13.19 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $777.9M. The 52-week trading range was $5.30 to $31.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.